Paradigm Biopharmaceuticals Ltd
ASX:PAR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Paradigm Biopharmaceuticals Ltd
Selling, General & Administrative
Paradigm Biopharmaceuticals Ltd
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Paradigm Biopharmaceuticals Ltd
ASX:PAR
|
Selling, General & Administrative
-AU$6m
|
CAGR 3-Years
15%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Selling, General & Administrative
-$50.7m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-7%
|
|
|
CSL Ltd
ASX:CSL
|
Selling, General & Administrative
-$2.7B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-12%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Selling, General & Administrative
-AU$3m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Selling, General & Administrative
-AU$192.6m
|
CAGR 3-Years
-51%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Selling, General & Administrative
-AU$5.3m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-11%
|
|
Paradigm Biopharmaceuticals Ltd
Glance View
Paradigm Biopharmaceuticals Ltd. is a biopharmaceutical company, engages in researching and developing therapeutic products for human use. The company is headquartered in Melbourne, Victoria. The company went IPO on 2015-08-19. The firm is developing and commercializing injectable Pentosan Polysulfate Sodium (PPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The firm focuses on repurposing PPS for the treatment of Osteoarthritis (OA) and bone marrow lesions (BML), chronic heart failure (CHF) and alphaviral arthritis (Ross River Virus and Chikungunya). Its product candidate PPS is a non-opioid drug treatment for the chronic pain and joint stiffness of Osteoarthritis. Its product candidate PPS is providing treatment for Mucopolysaccharidosis, an inherited defect in the catabolism of sulfated components of connective tissue known as glycosaminoglycans (GAGs). Its product candidate PPS is used to treat Ross River virus and Chikungunya, an arthritogenic alphaviruses transmitted by mosquito bites.
See Also
What is Paradigm Biopharmaceuticals Ltd's Selling, General & Administrative?
Selling, General & Administrative
-6m
AUD
Based on the financial report for Dec 31, 2025, Paradigm Biopharmaceuticals Ltd's Selling, General & Administrative amounts to -6m AUD.
What is Paradigm Biopharmaceuticals Ltd's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 5Y
1%
Over the last year, the Selling, General & Administrative growth was -13%. The average annual Selling, General & Administrative growth rates for Paradigm Biopharmaceuticals Ltd have been 15% over the past three years , 1% over the past five years .
